Home  /  Resource Library  /  Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia

Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia

Conclusion of study – A short oral course of vemurafenib was highly effective in patients with relapsed or refractory hairy-cell leukemia.